The use of WEGOVY in patients with type 1 diabetes mellitus or in combination with insulin has not been evaluated
Latest in health-care tech: OpenAI launches new initiative to speed up scientific discovery OpenAI is doubling down on health care innovation
Wegovy, another semaglutide drug prescribed specifically to treat obesity, will be offered on the NHS to those with a body mass index (BMI) of at least 35, and exceptionally, some people with a BMI of 30 and a weight-related health problem
Looking for support with OCD
The results appear promising, Hendershot says
The two practical considerations are gastric emptying, which is strongest when you start and after each dose increase, and weight loss, which reduces your levothyroxine requirement